Nunaps Inc.

Nunaps is pioneering “software medicine” for visual field defects, a condition affecting approximately 24% of stroke survivors with limited therapeutic options. Vividbrain is a VR-based digital medical device that delivers personalized visual perceptual training for 30 minutes a day over a 12-week treatment program. It applies Visual Perceptual Learning, integrating clinical neurology and brain science to promote neuroplasticity. Through repetitive and personalized visual stimuli, Vividbrain aims to reactivate dormant neural pathways and restore visual function—going beyond conventional approaches that focus primarily on compensation for vision loss.

Supported by clinical evidence published in JAMA Network Open, Vividbrain is currently prescribed across 30+ secondary and tertiary hospitals in Korea, with 500+ prescriptions since September 2024, 38% patient re-prescription, and a 149% patient compliance rate.

Following CE Class I approval in 2025, Nunaps is advancing its global expansion through DiGA and FDA pathways in Germany and the U.S. in 2027, followed by PMDA and China in 2028. Nunaps aims to establish Vividbrain as a new global standard in digital therapeutics for visual field defects.